Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomma Targets Prestige’s Objections To Takeover

This article was originally published in The Tan Sheet

Executive Summary

Genomma Lab shareholders approve an unsolicited bid for Prestige Brands with permission to up the ante. In another development that comes as Prestige closes the acquisition of 17 OTC brands from GSK, Prestige acknowledges Genomma’s slate of board nominees to be voted on at a June 29 shareholder meeting.

You may also be interested in...



Multinationals Turn To Smaller Markets To Avoid BRIC Restrictions

Poland, Mexico, South Korea and Indonesia all grew between 5% and 6.5% in 2011, and South Africa, Turkey, Vietnam, the “stans” countries and “fascinatingly” Iran, among others, also are likely areas for future expansion of the OTC and self-care market, consultant Nicholas Hall says.

Multinationals Turn To Smaller Markets To Avoid BRIC Restrictions

Poland, Mexico, South Korea and Indonesia all grew between 5% and 6.5% in 2011, and South Africa, Turkey, Vietnam, the “stans” countries and “fascinatingly” Iran, among others, also are likely areas for future expansion of the OTC and self-care market, consultant Nicholas Hall says.

In Brief

Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel